Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tobira, Dong-A Stick To NASH Plans Despite CENTAUR Results

Executive Summary

The failure of Tobira's cenicriviroc to meet its primary endpoint in the CENTAUR study has raised some concerns in South Korea over the prospects for a combo therapy with Dong-A ST's evogliptin. But the two firms are sticking to their clinical development plans based on the positive secondary endpoint outcome in the study.

Advertisement

Related Content

Allergan’s Tab For Tobira’s NASH Cocktail With Akarna Chaser Tops $1.7bn
Tobira Says Secondary Endpoint In NASH Will Carry CVC Into Pivotal Study
Dong-A Eyes Expanded Evogliptin Markets Via Tobira NASH Deal
With 29 Candidates Advancing, NASH Race May Hinge On Long-Duration Data

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel